Zai Lab Current Ratio 2016-2022 | ZLAB

Zai Lab current ratio from 2016 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zai Lab Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-09-30 $1.21B $0.16B 7.78
2022-06-30 $1.34B $0.17B 7.91
2022-03-31 $1.39B $0.16B 8.99
2021-12-31 $1.50B $0.19B 7.78
2021-09-30 $1.62B $0.11B 14.46
2021-06-30 $1.81B $0.19B 9.33
2021-03-31 $1.05B $0.09B 11.32
2020-12-31 $1.22B $0.10B 12.40
2020-09-30 $0.00B 0.00
2020-06-30 $0.49B $0.06B 8.57
2020-03-31 $0.00B 0.00
2019-12-31 $0.29B $0.05B 6.27
2019-09-30 $0.33B $0.04B 8.02
2019-06-30 $0.40B $0.05B 8.74
2018-12-31 $0.27B $0.05B 5.51
2017-12-31 $0.23B $0.01B 19.11
2017-06-30 $0.09B $0.01B 9.76
2016-12-31 $0.08B $0.01B 16.26
2015-12-31 $0.01B $0.00B 3.36
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $3.925B $0.144B
Zai Lab Ltd is a biopharmaceutical company. It focused on medicines for cancer, autoimmune and infectious diseases primarily in China. The company's product pipeline consists of ZL-2306, ZL-2401, ZL-2301, ZL-3101, ZL-2302 and ZL-1101 which are in clinical stage. Zai Lab Ltd is based in Pudong, China.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $158.293B 9.67
GSK (GSK) United Kingdom $71.300B 9.41
Bio-Rad Laboratories (BIO.B) United States $12.069B 28.64
QIAGEN (QGEN) Netherlands $11.249B 19.20
Ginkgo Bioworks Holdings (DNA) United States $3.996B 0.00
Myovant Sciences (MYOV) United Kingdom $2.614B 0.00
Arcus Biosciences (RCUS) United States $1.485B 22.29
Biohaven (BHVN) United States $1.240B 0.00
Emergent Biosolutions (EBS) United States $0.697B 5.48
ADC Therapeutics SA (ADCT) Switzerland $0.356B 0.00
Enzo Biochem (ENZ) United States $0.070B 0.00
Ambrx Biopharma (AMAM) United States $0.070B 0.00
SQZ Biotechnologies (SQZ) United States $0.024B 0.00
Gelesis Holdings (GLS) United States $0.024B 0.00